与培氟沙星、环丙沙星、氧氟沙星、多西环素和克拉霉素相比，伯氏考克斯体对曲伐沙星的体外敏感性。
In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.
作者信息
Gikas A, Spyridaki I, Psaroulaki A, Kofterithis D, Tselentis Y
机构信息
Clinical Bacteriology, Parasitology, Zoonoses, and Geographical Medicine, University Hospital of Heraklion, 1352/71110 Crete, Greece.
出版信息
Antimicrob Agents Chemother. 1998 Oct;42(10):2747-8. doi: 10.1128/AAC.42.10.2747.
Abstract
The antibiotic susceptibilities of eight Greek isolates of Coxiella burnetii to trovafloxacin were determined by the shell vial assay. MICs of trovafloxacin and ofloxacin ranged from 1 to 2 microg/ml, those of pefloxacin ranged from 1 to 4 microg/ml, those of ciprofloxacin ranged from 4 to 8 microg/ml, those of doxycycline ranged from 1 to 2 microg/ml, and those of clarithromycin ranged from 2 to 4 microg/ml. Trovafloxacin exhibited no activity against C. burnetii at 4 microg/ml.
摘要
通过空斑试验测定了8株希腊伯氏考克斯体分离株对曲伐沙星的抗生素敏感性。曲伐沙星和氧氟沙星的最低抑菌浓度（MIC）范围为1至2微克/毫升，培氟沙星的MIC范围为1至4微克/毫升，环丙沙星的MIC范围为4至8微克/毫升，多西环素的MIC范围为1至2微克/毫升，克拉霉素的MIC范围为2至4微克/毫升。曲伐沙星在4微克/毫升时对伯氏考克斯体无活性。
相似文献
1
In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.与培氟沙星、环丙沙星、氧氟沙星、多西环素和克拉霉素相比，伯氏考克斯体对曲伐沙星的体外敏感性。
Antimicrob Agents Chemother. 1998 Oct;42(10):2747-8. doi: 10.1128/AAC.42.10.2747.
2
In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.伯氏考克斯体对利奈唑胺的体外敏感性及其与喹诺酮类、多西环素和克拉霉素敏感性的比较
Antimicrob Agents Chemother. 2001 Nov;45(11):3276-8. doi: 10.1128/AAC.45.11.3276-3278.2001.
3
Susceptibility of Rickettsia conorii, R. rickettsii, and Coxiella burnetii to PD 127,391, PD 131,628, pefloxacin, ofloxacin, and ciprofloxacin.康氏立克次体、立氏立克次体和贝氏柯克斯体对PD 127,391、PD 131,628、培氟沙星、氧氟沙星和环丙沙星的敏感性。
Antimicrob Agents Chemother. 1992 Nov;36(11):2529-32. doi: 10.1128/AAC.36.11.2529.
4
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.替加环素对贝氏柯克斯体的抑菌和杀菌活性及其与其他六种抗生素的比较
Antimicrob Agents Chemother. 2009 Jun;53(6):2690-2. doi: 10.1128/AAC.01424-08. Epub 2009 Mar 30.
5
Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.莫西沙星对贝氏柯克斯体的抑菌和杀菌活性。
Antimicrob Agents Chemother. 2001 Jan;45(1):301-2. doi: 10.1128/AAC.45.1.301-302.2001.
6
In vitro activity of trovafloxacin against Chlamydia pneumoniae.曲伐沙星对肺炎衣原体的体外活性。
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
7
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.曲伐沙星与其他氟喹诺酮类药物对金黄色葡萄球菌纯化的拓扑异构酶以及gyrA和grlA突变体的活性比较。
Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845.
8
Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.铜绿假单胞菌体外角膜分离株对氧氟沙星、环丙沙星和曲伐沙星的敏感性：一项比较研究。
Am J Ophthalmol. 2001 Jun;131(6):795-6. doi: 10.1016/s0002-9394(00)00896-5.
9
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.曲伐沙星及其他五种氟喹诺酮类药物的体外抗菌活性
Chemotherapy. 1998 Mar-Apr;44(2):85-93. doi: 10.1159/000007097.
10
In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones.伯氏考克斯体对阿奇霉素、多西环素、环丙沙星及一系列新型氟喹诺酮类药物的体外敏感性
Int J Antimicrob Agents. 2004 Aug;24(2):194-6. doi: 10.1016/j.ijantimicag.2004.05.001.
引用本文的文献
1
Efficacy of rifapentine and other rifamycins against .利福喷丁和其他利福霉素类药物对 的疗效。
Microbiol Spectr. 2024 Jul 2;12(7):e0103424. doi: 10.1128/spectrum.01034-24. Epub 2024 Jun 12.
2
The microbiota changes of the brown dog tick, under starvation stress.饥饿胁迫下棕色犬蜱的微生物群变化
Front Physiol. 2022 Sep 9;13:932130. doi: 10.3389/fphys.2022.932130. eCollection 2022.
3
Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.神经递质系统靶向药物拮抗 Q 热病原体柯克斯体在人细胞中的生长。
mSphere. 2021 Aug 25;6(4):e0044221. doi: 10.1128/mSphere.00442-21. Epub 2021 Jul 7.
4
Antimicrobial Resistance in , , , and Other Intracellular Pathogens.,, 和其他细胞内病原体中的抗微生物药物耐药性。
Microbiol Spectr. 2018 Apr;6(2). doi: 10.1128/microbiolspec.ARBA-0003-2017.
5
From Q Fever to Coxiella burnetii Infection: a Paradigm Change.从Q热到伯氏考克斯氏体感染：范式转变
Clin Microbiol Rev. 2017 Jan;30(1):115-190. doi: 10.1128/CMR.00045-16.
6
Development of Liposomal Ciprofloxacin to Treat Lung Infections.用于治疗肺部感染的脂质体环丙沙星的研发。
Pharmaceutics. 2016 Mar 1;8(1):6. doi: 10.3390/pharmaceutics8010006.
7
Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.脂质体包裹环丙沙星在鼠型Q热模型中的疗效
Antimicrob Agents Chemother. 2014 Sep;58(9):5510-8. doi: 10.1128/AAC.03443-14. Epub 2014 Jul 7.
8
Antimicrobial therapies for Q fever.Q 热的抗菌治疗。
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1207-14. doi: 10.1586/14787210.2013.840534. Epub 2013 Sep 27.
9
Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.替加环素对贝氏柯克斯体的抑菌和杀菌活性及其与其他六种抗生素的比较
Antimicrob Agents Chemother. 2009 Jun;53(6):2690-2. doi: 10.1128/AAC.01424-08. Epub 2009 Mar 30.
10
Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.Q热心内膜炎治疗期间血清多西环素浓度与最低抑菌浓度之比与抗体水平快速下降之间的相关性。
Antimicrob Agents Chemother. 2005 Jul;49(7):2673-6. doi: 10.1128/AAC.49.7.2673-2676.2005.
本文引用的文献
1
Optimum treatment of intracellular infection.细胞内感染的最佳治疗方法。
Drugs. 1996 Jul;52(1):45-59. doi: 10.2165/00003495-199652010-00004.
2
In vitro activities of ceftriaxone and fusidic acid against 13 isolates of Coxiella burnetii, determined using the shell vial assay.采用空斑试验测定头孢曲松和夫西地酸对13株贝氏柯克斯体的体外活性。
Antimicrob Agents Chemother. 1993 Mar;37(3):491-4. doi: 10.1128/AAC.37.3.491.
3
Treatment of Q fever.Q热的治疗
Antimicrob Agents Chemother. 1993 Sep;37(9):1733-6. doi: 10.1128/AAC.37.9.1733.
4
In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.斑点热群立克次体和伯氏考克斯氏体对克拉霉素的体外敏感性
Antimicrob Agents Chemother. 1993 Dec;37(12):2633-7. doi: 10.1128/AAC.37.12.2633.
5
The inhibitory effect of fluoroquinolones on Coxiella burnetii growth in in-vitro systems.
J Antimicrob Chemother. 1994 Jun;33(6):1253-5. doi: 10.1093/jac/33.6.1254.
6
Q fever.Q热
Clin Infect Dis. 1995 Mar;20(3):489-95; quiz 496. doi: 10.1093/clinids/20.3.489.
7
Q fever in the Greek Island of Crete: epidemiologic, clinical, and therapeutic data from 98 cases.
Clin Infect Dis. 1995 May;20(5):1311-6. doi: 10.1093/clinids/20.5.1311.
8
In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones.伯纳特柯克斯体对包括几种喹诺酮类药物在内的抗生素的体外敏感性。
Antimicrob Agents Chemother. 1987 Jul;31(7):1079-84. doi: 10.1128/AAC.31.7.1079.
9
Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis.32例Q热心内膜炎不同抗生素治疗方案的比较。
Antimicrob Agents Chemother. 1991 Mar;35(3):533-7. doi: 10.1128/AAC.35.3.533.
10
Antibiotic treatment of rickettsiosis, recent advances and current concepts.立克次体病的抗生素治疗：最新进展与当前理念
Eur J Epidemiol. 1991 May;7(3):276-81. doi: 10.1007/BF00145677.
Zotero 插件